The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD.
Walton MI, et al. Among authors: tall m.
Oncotarget. 2016 Jan 19;7(3):2329-42. doi: 10.18632/oncotarget.4919.
Oncotarget. 2016.
PMID: 26295308
Free PMC article.